Tempus AI (NASDAQ:TEM) Trading Up 3.5% - Should You Buy?

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report)'s share price traded up 3.5% during mid-day trading on Friday . The company traded as high as $49.40 and last traded at $49.72. 2,849,544 shares were traded during mid-day trading, a decline of 43% from the average session volume of 5,025,887 shares. The stock had previously closed at $48.04.

Analyst Ratings Changes

A number of equities research analysts have commented on TEM shares. Wolfe Research lowered shares of Tempus AI from a "strong-buy" rating to a "hold" rating in a report on Wednesday, February 26th. TD Cowen reissued a "buy" rating and issued a $74.00 price target (up previously from $58.00) on shares of Tempus AI in a report on Wednesday, February 5th. Piper Sandler reduced their price objective on Tempus AI from $70.00 to $55.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. William Blair reissued a "market perform" rating on shares of Tempus AI in a research note on Tuesday, February 25th. Finally, Guggenheim reaffirmed a "buy" rating on shares of Tempus AI in a research note on Tuesday, February 25th. Six analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $61.18.

Tempus AI Stock Up 12.6 %

The stock's fifty day moving average is $56.35 and its 200-day moving average is $51.38. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69.

Remove Ads

Insider Activity at Tempus AI

In other Tempus AI news, CEO Eric P. Lefkofsky sold 3,240,234 shares of the firm's stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $58.75, for a total transaction of $190,363,747.50. Following the sale, the chief executive officer now directly owns 4,895,589 shares in the company, valued at approximately $287,615,853.75. This trade represents a 39.83 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director David R. Epstein sold 990 shares of Tempus AI stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $46.83, for a total transaction of $46,361.70. Following the completion of the transaction, the director now directly owns 26,284 shares in the company, valued at approximately $1,230,879.72. The trade was a 3.63 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 5,598,969 shares of company stock worth $317,194,162 in the last quarter.

Institutional Investors Weigh In On Tempus AI

Hedge funds and other institutional investors have recently bought and sold shares of the company. Wells Fargo & Company MN grew its stake in shares of Tempus AI by 13.2% during the 4th quarter. Wells Fargo & Company MN now owns 2,384 shares of the company's stock worth $80,000 after acquiring an additional 278 shares in the last quarter. First Horizon Advisors Inc. acquired a new position in shares of Tempus AI during the 3rd quarter worth about $30,000. Geode Capital Management LLC increased its stake in shares of Tempus AI by 0.4% during the 3rd quarter. Geode Capital Management LLC now owns 133,171 shares of the company's stock worth $7,537,000 after purchasing an additional 539 shares during the last quarter. Operose Advisors LLC bought a new stake in shares of Tempus AI in the 4th quarter valued at about $25,000. Finally, Prestige Wealth Management Group LLC lifted its stake in Tempus AI by 910.4% in the 4th quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company's stock valued at $36,000 after purchasing an additional 965 shares during the last quarter. Institutional investors and hedge funds own 24.22% of the company's stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.